MannKind has said that it reached a final resolution of the arbitration proceedings initiated by John Arditi, the company’s former senior director of good clinical practices within the regulatory affairs group who had sued the company claiming he was retaliated against for raising concerns about the clinical trials for the inhaled insulin Afrezzo (insulin human rDNA origin) conducted in Russia and Bulgaria.
The former employee held a key position at the firm involved with preparing clinical sites for FDA inspection, and was...
